HC Wainwright Reiterates Buy Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)

HC Wainwright restated their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research report report published on Friday,Benzinga reports. HC Wainwright currently has a $200.00 price target on the specialty pharmaceutical company’s stock.

JAZZ has been the topic of a number of other reports. Wells Fargo & Company decreased their target price on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a report on Thursday, August 1st. TD Cowen cut their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. Piper Sandler reiterated an “overweight” rating and issued a $163.00 price target (down previously from $166.00) on shares of Jazz Pharmaceuticals in a research note on Thursday. StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $140.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Three investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $175.33.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock opened at $126.67 on Friday. Jazz Pharmaceuticals has a one year low of $99.06 and a one year high of $134.17. The stock’s fifty day moving average is $113.65 and its 200 day moving average is $110.73. The stock has a market cap of $7.66 billion, a P/E ratio of 17.84, a P/E/G ratio of 1.05 and a beta of 0.57. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Insider Activity

In related news, EVP Neena M. Patil sold 3,700 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the transaction, the executive vice president now owns 33,048 shares in the company, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $110.84, for a total value of $110,840.00. Following the completion of the transaction, the chief executive officer now owns 428,976 shares of the company’s stock, valued at approximately $47,547,699.84. This represents a 0.23 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,110 shares of company stock worth $720,160 over the last 90 days. Corporate insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in JAZZ. Swedbank AB purchased a new position in Jazz Pharmaceuticals in the second quarter worth about $106,936,000. Rubric Capital Management LP purchased a new position in Jazz Pharmaceuticals in the second quarter worth about $65,812,000. Pacer Advisors Inc. grew its position in Jazz Pharmaceuticals by 40.7% in the second quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company’s stock worth $194,346,000 after acquiring an additional 527,187 shares in the last quarter. Baupost Group LLC MA grew its position in Jazz Pharmaceuticals by 52.8% in the second quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock worth $136,000,000 after acquiring an additional 440,552 shares in the last quarter. Finally, Millennium Management LLC grew its position in Jazz Pharmaceuticals by 1,808.4% in the second quarter. Millennium Management LLC now owns 450,872 shares of the specialty pharmaceutical company’s stock worth $48,122,000 after acquiring an additional 427,246 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.